Furthermore, there is a possibility that such treatment potentiates the efficiency of dupilumab, an IL-4 receptor α-antagonist that inhibits IL-4/STAT6 signaling, in the treatment of AD. The gene discussed is IL4; the disease is Alzheimer disease.